Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging

[1]  J. Cuzick,et al.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.

[2]  R. Paridaens,et al.  First mature analysis of the Intergroup Exemestane Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Brufsky.  Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. , 2006, Seminars in oncology.

[4]  J. Manson,et al.  Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study , 2005, BMJ : British Medical Journal.

[5]  P. Neven,et al.  Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting , 2005, Current opinion in oncology.

[6]  S. Cummings,et al.  Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. , 2005, Arthritis and rheumatism.

[7]  Michael Gnant,et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.

[8]  W. Gradishar.  Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women , 2005, Oncology.

[9]  Chiara Benedetto,et al.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Ingle.  Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[12]  E. van Limbergen,et al.  Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients , 2004, Anti-cancer drugs.

[13]  P. Lønning,et al.  A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer. , 2004 .

[14]  E. Perez,et al.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.

[15]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[16]  R. Penson,et al.  Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Goss.  Risks versus benefits in the clinical application of aromatase inhibitors. , 1999, Endocrine-related cancer.

[18]  P. Lønning,et al.  Aromatase inhibitors as adjuvant treatment of breast cancer. , 2006, Critical reviews in oncology/hematology.

[19]  R. Leonard,et al.  Aromatase inhibitors and arthralgia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.